Browsing by Author Zhu, Andrew X.
Showing results 1 to 8 of 8
| Issue Date | Title | Author(s) |
|---|---|---|
| 13-Nov-2020 | Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2 | Kudo, Masatoshi; Galle, Peter R.; Brandi, Giovanni; Kang, Yoon Koo; Yen, Chia Jui; Finn, Richard S.; Llovet i Bayer, Josep Maria; Assenat, Eric; Merle, Philippe; Chan, Stephen L.; Palmer, Daniel H.; Ikeda, Masafumi; Yamashita, Tatsuya; Vogel, Arndt; Huang, Yi Hsiang; Abada, Paolo; Yoshikawa, Reigetsu; Shinozaki, Kenta; Wang, Chunxiao; Widau, Ryan C.; Zhu, Andrew X. |
| 2-Jul-2014 | Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer | Saha, Supriya K.; Parachoniak, Christine A.; Ghanta, Krishna S.; Fitamant, Julien; Ross, Kenneth N.; Najem, Mortada S.; Gurumurthy, Sushma; Akbay, Esra A.; Sia, Daniela; Cornella, Helena; Miltiadous, Oriana; Walesky, Chad; Deshpande, Vikram; Zhu, Andrew X.; Hezel, Aram F.; Yen, Katharine E.; Straley, Kimberly S.; Travins, Jeremy; Popovici-Muller, Janeta; Gliser, Camelia; Ferrone, Cristina R.; Apte, Udayan; Llovet i Bayer, Josep Maria; Wong, Kwok-Kin; Ramaswamy, Sridhar; Bardeesy, Nabeel |
| 14-Nov-2020 | Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab | Reig, María; Galle, Peter R.; Kudo, Masatoshi; Finn, Richard; Llovet i Bayer, Josep Maria; Metti, Andrea L.; Schelman, William R.; Liang, Kun; Wang, Chunxiao; Widau, Ryan C.; Abada, Paolo; Zhu, Andrew X. |
| 27-Jul-2020 | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma | Finn, Richard S.; Ikeda, Masafumi; Zhu, Andrew X.; Sung, Max W.; Baron, Ari D.; Kudo, Masatoshi; Okusaka, Takuji; Kobayashi, Masahiro; Kumada, Hiromitsu; Kaneko, Shuichi; Pracht, Marc; Mamontov, Konstantin; Meyer, Tim; Kubota, Tomoki; Dutcus, Corina E.; Saito, Kenichi; Siegel, Abby B.; Dubrovsky, Leonid; Mody, Kalgi; Llovet i Bayer, Josep Maria |
| Aug-2020 | Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2 | Kudo, Masatoshi; Galle, Peter R.; Llovet i Bayer, Josep Maria; Finn, Richard S.; Vogel, Arndt; Motomura, Kenta; Assenat, Eric; Merle, Philippe; Brandi, Giovanni; Daniele, Bruno; Okusaka, Takuji; Tomášek, Jiří; Borg, Christophe; Dadduzio, Vincenzo; Morimoto, Manabu; Pracht, Marc; Jen, Min-Hua; Widau, Ryan C.; Shinozaki, Kenta; Yoshikawa, Reigetsu; Zhu, Andrew X. |
| 1-Jan-2020 | Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials | Zhu, Andrew X.; Nipp, Ryan D.; Finn, Richard S.; Galle, Peter R.; Llovet i Bayer, Josep Maria; Blanc, Jean Frederic; Okusaka, Takuji; Chau, Ian; Cella, David; Girvan, Alicia; Gable, Jonathon; Bowman, Lee; Wang, Chunxiao; Hsu, Yanzhi; Abada, Paolo; Kudo, Masatoshi |
| 20-Feb-2014 | Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma | Zhu, Andrew X.; Rosmorduc, Olivier; Evans, T.R. Jeffry; Ross, Paul J.; Santoro, Armando; Carrilho, Flair José; Bruix Tudó, Jordi; Qin, Shukui; Thuluvath, Paul J.; Llovet i Bayer, Josep Maria; Leberre, Marie-Aude; Jensen, Markus; Meinhardt, Gerold; Kang, Yoon-Koo |
| 17-Mar-2015 | YAP Inhibition restores Hepatocyte differentiation in advanced HCC, leading to tumor regression | Fitamant, Julien; Kottakis, Filippos; Benhamouche, Samira; Tian, Helen S.; Chuvin, Nicolas; Parachoniak, Christine A.; Nagle, Julia M.; Perera, Rushika M.; Lapouge, Marjorie; Deshpande, Vikram; Zhu, Andrew X.; Lai, Albert; Min, Bosun; Hoshida, Yujin; Avruch, Joseph; Sia, Daniela; Campreciós Figueras, Genís; McClatchey, Andrea I.; Llovet i Bayer, Josep Maria; Morrissey, David; Raj, Lakshmi; Bardeesy, Nabeel |